rani: the cashflow

MyFinsight

For the quarter ending 2025-09-30.

Unit: Thousand (K) dollars (except for numbers of shares and EPS)

Cash Flow	2025-09-30	2025-06-30
Net cash (used in)/provided by financing activities	-4,552	-3,543
Net increase/(decrease) in cash, cash equivalents and restricted cash equivalents	382	6,454
Cash and cash equivalents at beginning of period	4,262	-
Cash and cash equivalents at end of period	4,644	-

Unit: Thousand (K) dollars (except for numbers of shares and EPS)

For the quarter ending 2025-09-30.

Unit: Thousand (K) dollars (except for numbers of shares and EPS)

Cash Flow	2025-09-30	2025-06-30
Net cash (used in)/provided by financing activities	-4,552	-3,543
Net increase/(decrease) in cash, cash equivalents and restricted cash equivalents	382	6,454
Cash and cash equivalents at beginning of period	4,262	-
Cash and cash equivalents at end of period	4,644	-

Unit: Thousand (K) dollars (except for numbers of shares and EPS)

Rani Therapeutics Holdings, Inc. (RANI)